The first large-scale study has demonstrated that eszopiclone effectively treats long-term insomnia. (Insomnia is defined as the perception of inadequate or poorquality sleep, accompanied by significant distress or impaired function. It is considered chronic if it occurs on most nights and lasts 1 month.)
In the 6-month, randomized, double-blind, placebo-controlled study, 788 patients aged 21 to 69 were given 3 mg of eszopiclone nightly. The study revealed that doses of the drug led to dramatic improvement in patients? ability to fall asleep and stay asleep and in the quality of their sleep, without any evidence of a loss of effect over time. Also, the results showed that sleep improvements were associated with consistent improvement in the patients? ratings of their ability to function well every day. (The findings were published in Sleep, November 1, 2003.)
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs